RPG Life Sciences Ltd: Fundamental Analysis, Share Price Insights & Intrinsic Value (2024)

Share Price and Basic Stock Data

Last Updated: December 21, 2024, 1:55 am

Market Cap	3,655 Cr.
Current Price	2,210
High / Low	2,977/1,306
Stock P/E	42.0
Book Value	229
Dividend Yield	0.72 %
ROCE	34.6 %
ROE	25.5 %
Face Value	8.00
PEG Ratio	3.48

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for

Competitors of

Stock Name	Market Cap	Current Price	High / Low	Stock P/E	Book Value	Dividend Yield	ROCE	ROE	Face Value
Gujarat Themis Biosyn Ltd	3,354 Cr.	308	390/128	63.6	20.5	0.22 %	45.0 %	33.8 %	1.00
Gujarat Terce Laboratories Ltd	62.6 Cr.	84.4	94.9/26.6	24.0	11.9	0.00 %	9.72 %	3.44 %	10.0
Gujarat Inject (Kerala) Ltd	35.9 Cr.	24.5	24.5/8.74	46.6	6.64	0.00 %	2.65 %	2.08 %	10.0
Godavari Drugs Ltd	86.7 Cr.	115	155/87.0	13.0	55.4	0.00 %	14.4 %	15.5 %	10.0
Glenmark Life Sciences Ltd	12,416 Cr.	1,013	1,335/645	29.3	207	2.22 %	28.1 %	21.1 %	2.00
Industry Average	14,994.84	N/A		46.07	N/A	N/A	16.07	15.77	N/A

All Competitor Stocks of

Quarterly Result

Month	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Sales	112.65	115.58	103.80	128.93	134.79	130.60	118.49	147.78	153.58	153.70	126.99	165.42	172.21
Expenses	86.85	91.48	90.29	101.09	105.06	101.39	102.58	115.54	116.29	115.80	106.27	126.35	126.28
Operating Profit	25.80	24.10	13.51	27.84	29.73	29.21	15.91	32.24	37.29	37.90	20.72	39.07	45.93
OPM %	22.90%	20.85%	13.02%	21.59%	22.06%	22.37%	13.43%	21.82%	24.28%	24.66%	16.32%	23.62%	26.67%
Other Income	0.71	0.61	1.26	1.22	1.23	0.51	1.84	1.81	1.83	1.92	1.65	2.37	-25.36
Interest	0.17	0.16	0.06	0.11	0.08	0.07	0.05	0.07	0.10	0.14	0.14	0.15	0.17
Depreciation	3.99	3.93	3.78	3.83	3.87	3.91	3.89	4.21	4.23	4.14	4.49	5.29	5.31
Profit before tax	22.35	20.62	10.93	25.12	27.01	25.74	13.81	29.77	34.79	35.54	17.74	36.00	15.09
Tax %	29.53%	29.05%	31.20%	27.51%	26.06%	25.76%	25.05%	25.76%	25.67%	25.55%	25.37%	25.67%	72.17%
Net Profit	15.75	14.63	7.52	18.21	19.97	19.11	10.35	22.10	25.86	26.46	13.24	26.76	4.20
EPS in Rs	9.52	8.85	4.55	11.01	12.07	11.55	6.26	13.36	15.64	16.00	8.01	16.18	2.54

Last Updated: November 18, 2024, 4:59 pm

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: November 18, 2024, 4:59 pm

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	TTM
Sales	222	236	242	279	294	344	330	376	389	440	513	582	618
Expenses	206	224	228	256	274	306	296	315	318	353	408	453	475
Operating Profit	16	12	14	23	20	38	34	60	71	87	104	129	144
OPM %	7%	5%	6%	8%	7%	11%	10%	16%	18%	20%	20%	22%	23%
Other Income	2	66	1	1	18	1	1	-5	1	3	4	7	-19
Interest	7	3	3	2	4	5	5	3	2	1	1	1	1
Depreciation	10	11	11	10	11	14	15	16	16	16	16	17	19
Profit before tax	1	65	1	12	23	20	15	36	54	73	92	118	104
Tax %	-717%	18%	0%	0%	10%	34%	28%	20%	25%	30%	26%	26%
Net Profit	4	53	1	12	21	13	11	29	40	51	68	88	71
EPS in Rs	2.67	32.29	0.60	7.03	12.70	8.13	6.54	17.54	24.19	31.13	40.90	53.00	42.73
Dividend Payout %	45%	6%	132%	23%	22%	30%	37%	23%	30%	31%	29%	30%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2013-2014	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024
YoY Net Profit Growth (%)	1225.00%	-98.11%	1100.00%	75.00%	-38.10%	-15.38%	163.64%	37.93%	27.50%	33.33%	29.41%
Change in YoY Net Profit Growth (%)	0.00%	-1323.11%	1198.11%	-1025.00%	-113.10%	22.71%	179.02%	-125.71%	-10.43%	5.83%	-3.92%

has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:	9%
5 Years:	12%
3 Years:	14%
TTM:	12%

Compounded Profit Growth
10 Years:	37%
5 Years:	52%
3 Years:	30%
TTM:	12%

Stock Price CAGR
10 Years:	38%
5 Years:	47%
3 Years:	54%
1 Year:	62%

Return on Equity
10 Years:	17%
5 Years:	23%
3 Years:	24%
Last Year:	25%

Last Updated: Unknown

Balance Sheet

Last Updated: November 14, 2024, 7:45 pm

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Sep 2024
Equity Capital	13	13	13	13	13	13	13	13	13	13	13	13	13
Reserves	63	113	112	120	134	142	147	163	203	243	294	362	366
Borrowings	63	15	33	23	45	54	36	12	2	1	0	0	0
Other Liabilities	67	56	39	49	55	82	54	78	85	88	112	138	175
Total Liabilities	206	196	197	205	247	291	251	267	303	345	419	513	554
Fixed Assets	103	106	105	109	137	131	128	123	113	104	124	114	193
CWIP	1	1	1	2	2	9	17	10	12	31	25	96	14
Investments	0	0	0	0	0	0	0	0	0	0	58	91	93
Other Assets	102	89	92	94	108	152	106	134	178	210	211	212	254
Total Assets	206	196	197	205	247	291	251	267	303	345	419	513	554

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Cash from Operating Activity +	12	-6	-2	33	7	15	46	50	58	65	91	94
Cash from Investing Activity +	-12	59	-10	-15	-30	-16	-19	-11	-8	-35	-106	-79
Cash from Financing Activity +	-0	-54	12	-18	23	0	-26	-39	-10	-14	-17	-20
Net Cash Flow	0	0	-0	-0	1	-1	0	0	40	17	-32	-5

Free Cash Flow

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Free Cash Flow	-47.00	-3.00	-19.00	0.00	-25.00	-16.00	-2.00	48.00	69.00	86.00	104.00	129.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Debtor Days	81	56	61	48	49	72	43	62	54	27	27	31
Inventory Days	140	180	149	156	163	171	136	133	162	214	203	200
Days Payable	226	176	109	135	102	165	83	127	132	117	138	140
Cash Conversion Cycle	-5	60	101	70	110	78	96	68	84	124	91	90
Working Capital Days	46	51	76	54	50	62	53	46	53	47	33	25
ROCE %	6%	2%	2%	9%	10%	13%	10%	23%	27%	31%	33%	35%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Promoters	72.07%	72.07%	72.41%	72.62%	72.62%	72.82%	72.82%	72.82%	72.82%	72.82%	72.82%	72.82%
FIIs	0.20%	0.12%	0.15%	0.08%	0.25%	0.38%	0.33%	0.46%	0.56%	0.90%	1.15%	1.35%
DIIs	0.01%	0.01%	0.01%	0.03%	0.01%	0.11%	0.27%	1.57%	1.77%	2.16%	2.61%	5.45%
Public	27.72%	27.80%	27.43%	27.27%	27.11%	26.70%	26.58%	25.15%	24.85%	24.12%	23.44%	20.40%
No. of Shareholders	22,768	22,821	22,115	20,757	21,360	20,837	20,226	21,088	21,866	22,137	22,232	23,481

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund Name	No of Shares	AUM (%)	Amount Invested (Cr)	Previous Number of Shares	Previous Date	Percentage Change
Mirae Asset Multicap Fund	165,269	1.18	22.98	165,269	2024-12-16	0%
Motilal Oswal S&P BSE Healthcare ETF	47	0.07	0.01	165,269	2024-12-16	-99.97%

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20
FaceValue	8.00	8.00	8.00	8.00	8.00
Basic EPS (Rs.)	53.01	40.90	31.13	24.19	17.54
Diluted EPS (Rs.)	53.01	40.90	31.13	24.19	17.54
Cash EPS (Rs.)	63.33	50.27	40.60	34.15	27.43
Book Value[Excl.RevalReserv]/Share (Rs.)	226.67	186.00	154.66	130.88	106.77
Book Value[Incl.RevalReserv]/Share (Rs.)	226.67	186.00	154.66	130.88	106.77
Dividend / Share (Rs.)	16.00	12.00	9.60	7.20	4.00
Revenue From Operations / Share (Rs.)	351.96	310.09	266.16	235.31	227.10
PBDIT / Share (Rs.)	81.85	65.00	54.03	42.84	36.21
PBIT / Share (Rs.)	71.53	55.62	44.56	32.88	26.32
PBT / Share (Rs.)	71.26	55.44	44.24	32.40	22.04
Net Profit / Share (Rs.)	53.01	40.90	31.13	24.19	17.54
PBDIT Margin (%)	23.25	20.96	20.29	18.20	15.94
PBIT Margin (%)	20.32	17.93	16.74	13.97	11.58
PBT Margin (%)	20.24	17.87	16.62	13.76	9.70
Net Profit Margin (%)	15.06	13.19	11.69	10.27	7.72
Return on Networth / Equity (%)	23.38	21.98	20.12	18.48	16.42
Return on Capital Employeed (%)	30.97	29.05	27.86	24.30	23.63
Return On Assets (%)	17.09	16.12	14.93	13.18	10.87
Long Term Debt / Equity (X)	0.00	0.00	0.00	0.00	0.01
Total Debt / Equity (X)	0.00	0.00	0.00	0.01	0.03
Asset Turnover Ratio (%)	1.25	1.34	1.36	1.37	1.45
Current Ratio (X)	2.28	2.57	2.58	2.21	1.52
Quick Ratio (X)	1.50	1.64	1.55	1.47	0.95
Inventory Turnover Ratio (X)	1.23	0.96	1.25	1.63	1.71
Dividend Payout Ratio (NP) (%)	22.64	23.47	23.13	0.00	36.50
Dividend Payout Ratio (CP) (%)	18.95	19.10	17.73	0.00	23.34
Earning Retention Ratio (%)	77.36	76.53	76.87	0.00	63.50
Cash Earning Retention Ratio (%)	81.05	80.90	82.27	0.00	76.66
Interest Coverage Ratio (X)	300.80	346.74	171.83	89.67	34.22
Interest Coverage Ratio (Post Tax) (X)	195.80	219.19	100.00	51.63	20.62
Enterprise Value (Cr.)	2494.10	1093.81	855.55	600.68	287.41
EV / Net Operating Revenue (X)	4.29	2.13	1.94	1.54	0.76
EV / EBITDA (X)	18.43	10.18	9.58	8.48	4.80
MarketCap / Net Operating Revenue (X)	4.35	2.24	2.10	1.65	0.75
Retention Ratios (%)	77.35	76.52	76.86	0.00	63.49
Price / BV (X)	6.75	3.74	3.62	2.96	1.60
Price / Net Operating Revenue (X)	4.35	2.24	2.10	1.65	0.75
EarningsYield	0.03	0.05	0.05	0.06	0.10

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of as of December 22, 2024 is: 2,470.25

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of December 22, 2024, is Undervalued by 11.78% compared to the current share price 2,210.00

Intrinsic Value of as of December 22, 2024 is: 2,767.96

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of December 22, 2024, is Undervalued by 25.25% compared to the current share price 2,210.00

Last 5 Year EPS CAGR: 12.05%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The stock has a high average ROCE of 16.75%, which is a positive sign. The company has higher reserves (189.38 cr) compared to borrowings (21.85 cr), indicating strong financial stability. The company has shown consistent growth in sales (374.23 cr) and profit (47.23 cr) over the years.	The stock has a high average Working Capital Days of 49.67, which may not be favorable. The stock has a high average Cash Conversion Cycle of 80.58, which may not be favorable.

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in :
1. Net Profit Margin: 15.06%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 30.97% (Industry Average ROCE: 16.07%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: 23.38% (Industry Average ROE: 15.77%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 195.8
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 1.5
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 42 (Industry average Stock P/E: 46.07)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

RPG Life Sciences Ltd. is a Public Limited Listed company incorporated on 29/03/2007 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24232MH2007PLC169354 and registration number is 169354. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 440.16 Cr. and Equity Capital is Rs. 13.23 Cr. for the Year ended 31/03/2022.

INDUSTRY	ADDRESS	CONTACT
Pharmaceuticals	RPG House, Mumbai Maharashtra 400030	investorservices@rpgls.com http://www.rpglifesciences.com

Management
Name	Position Held
Mr. Harsh V Goenka	Chairman
Mr. Yugal Sikri	Managing Director
Mr. Rajat Bhargava	Non Executive Director
Mr. Sachin Nandgaonkar	Independent Director
Mr. Manoj K Maheshwari	Independent Director
Mr. Narendra Ambwani	Independent Director
Ms. Zahabiya Khorakiwala	Independent Director
Mr. Bhaskar Iyer	Independent Director
Dr. Lalit S Kanodia	Independent Director
Mr. Mahesh S Gupta	Independent Director
Mr. Hiten Kotak	Independent Director
Mr. Anil Matai	Independent Director
Ms. Radhika Gupta	Independent Director

FAQ

What is the latest intrinsic value of ?

The latest intrinsic value of as on 22 December 2024 is ₹2470.25, which is 11.78% higher than the current market price of ₹2,210.00. The stock has a market capitalization of 3,655 Cr. and recorded a high/low of 2,977/1,306 during the current fiscal year 2024-2025. As of Sep 2024, the company has reserves of ₹366 Cr and total liabilities of ₹554 Cr.

What is the Market Cap of ?

The Market Cap of is 3,655 Cr..

What is the current Stock Price of as on 22 December 2024?

The current stock price of as on 22 December 2024 is 2,210.

What is the High / Low of stocks in FY 2024-2025?

In FY 2024-2025, the High / Low of stocks is 2,977/1,306.

What is the Stock P/E of ?

The Stock P/E of is 42.0.

What is the Book Value of ?

The Book Value of is 229.

What is the Dividend Yield of ?

The Dividend Yield of is 0.72 %.

What is the ROCE of ?

The ROCE of is 34.6 %.

What is the ROE of ?

The ROE of is 25.5 %.

What is the Face Value of ?

The Face Value of is 8.00.